These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27336608)

  • 1. Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
    Zhang H; Shao H; Golubovskaya VM; Chen H; Cance W; Adjei AA; Dy GK
    Br J Cancer; 2016 Jul; 115(2):203-11. PubMed ID: 27336608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
    Heffler M; Golubovskaya VM; Dunn KM; Cance W
    Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
    Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
    Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
    Hochwald SN; Nyberg C; Zheng M; Zheng D; Wood C; Massoll NA; Magis A; Ostrov D; Cance WG; Golubovskaya VM
    Cell Cycle; 2009 Aug; 8(15):2435-43. PubMed ID: 19571674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
    Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM
    Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.
    Golubovskaya V; O'Brien S; Ho B; Heffler M; Conroy J; Hu Q; Wang D; Liu S; Cance WG
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1613-31. PubMed ID: 25656374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
    Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
    J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.
    Zhengfu H; Hu Z; Huiwen M; Zhijun L; Jiaojie Z; Xiaoyi Y; Xiujun C
    Biochem Biophys Res Commun; 2015 Aug; 464(2):422-7. PubMed ID: 26102035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
    Golubovskaya VM; Virnig C; Cance WG
    Mol Carcinog; 2008 Mar; 47(3):222-34. PubMed ID: 17849451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
    Phuchareon J; McCormick F; Eisele DW; Tetsu O
    Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
    Tang KJ; Constanzo JD; Venkateswaran N; Melegari M; Ilcheva M; Morales JC; Skoulidis F; Heymach JV; Boothman DA; Scaglioni PP
    Clin Cancer Res; 2016 Dec; 22(23):5851-5863. PubMed ID: 27220963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    Mol Cancer; 2005 Oct; 4():37. PubMed ID: 16209712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
    Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP
    Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
    Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
    Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics.
    O'Brien S; Golubovskaya VM; Conroy J; Liu S; Wang D; Liu B; Cance WG
    Oncotarget; 2014 Sep; 5(17):7945-59. PubMed ID: 25277206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.
    Heffler M; Golubovskaya VM; Conroy J; Liu S; Wang D; Cance WG; Dunn KB
    Anticancer Agents Med Chem; 2013 May; 13(4):584-94. PubMed ID: 22934709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.